About nirsevimab
Long-acting monoclonal antibody
Used for
- Prevents serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants.
- Protects certain children up to 24 months who remain at risk during their second RSV season.
Usual dose in children
Under 5 kg: 50 mg once. At least 5 kg: 100 mg once. Second RSV season for eligible high-risk children: 200 mg once.
Common side effects
- Rash
- Fever
- Injection-site reactions
Important warnings
- Not a treatment for an existing RSV infection.
- Seek urgent care for signs of a severe allergic reaction, such as breathing difficulty or facial swelling.
- Use cautiously with bleeding disorders or low platelet counts because it is injected into muscle.
Pregnancy
Not applicable; this medicine is for infants and young children.
Breastfeeding
Not applicable; this medicine is for infants and young children.
Interactions
- May be given with routine childhood vaccines; separate syringes and injection sites are used.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.